A Comparison of Dapsone and Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

This study has been completed.

First Received: November 2, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	Jacobus Pharmaceutical
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002283

Purpose

Evaluate the effectiveness rate of dapsone plus trimethoprim as a therapy for the first episode of Pneumocystis carinii pneumonia (PCP) in AIDS patients. Compare the rates and severity of adverse effects using dapsone versus trimethoprim - sulfamethoxazole (TMP / PurposeX). Establish relative toxicities with regard to suitability for outpatient treatment.

Condition	Intervention
Pneumonia, Pneumocystis Carinii HIV Infections	Drug: Trimethoprim Drug: Sulfamethoxazole Drug: Dapsone

Study Type:	Interventional
Study Design:	Treatment, Randomized
Official Title:	Randomized Prospective Study of Dapsone Versus Trimethoprim-Sulfamethoxazole in the Treatment of First Episode Pneumocystis Carinii Pneumonia in AIDS Patients

Resource links provided by NLM:

MedlinePlus related topics: AIDS Pneumonia

Drug Information available for: Dapsone Sulfamethoxazole Trimethoprim Trimethoprim-sulfamethoxazole combination

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Exclusion Criteria

Concurrent Medication:

Excluded:

Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).

Patients with the following are excluded:

History of allergic reaction to dapsone.
Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).
Patients subsequently found to be glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from the study and treated with another regimen.

Prior Medication:

Excluded:

Requirement for other medications found to be effective in the treatment of Pneumocystis carinii pneumonia (PCP) (i.e., DFMO, pyrimethamine, and sulfadiazine).

Patients who are glucose-6-phosphate dehydrogenase (G6PD) positive will be withdrawn from the study and treated with another regimen.

Hospitalized patients with first episode of Pneumocystis carinii pneumonia (PCP) documented by GIEMSA or methenamine stain.

Patients must:
Be willing and able to give informed consent.
Be expected to survive 1 week without therapy.
Have less than 48 hours of treatment for Pneumocystis carinii pneumonia (PCP) for this episode.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002283

Locations

United States, New Jersey
Jacobus Pharmaceutical Co
Princeton, New Jersey, United States, 08540

Sponsors and Collaborators

Jacobus Pharmaceutical

More Information

No publications provided

Study ID Numbers:	007A
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002283 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Trimethoprim-Sulfamethoxazole Combination
AIDS-Related Opportunistic Infections
Pneumonia, Pneumocystis carinii
Dapsone
Acquired Immunodeficiency Syndrome

Additional relevant MeSH terms:

Anti-Infective Agents
Communicable Diseases
Antiprotozoal Agents
Sexually Transmitted Diseases, Viral
Trimethoprim
Slow Virus Diseases
Molecular Mechanisms of Pharmacological Action
Trimethoprim-Sulfamethoxazole Combination
Renal Agents
Infection
Anti-Bacterial Agents
Antimalarials
Pneumonia, Pneumocystis
Mycoses
Antiparasitic Agents

Respiratory Tract Diseases
Respiratory Tract Infections
Therapeutic Uses
Dapsone
Retroviridae Infections
Lung Diseases, Fungal
RNA Virus Infections
Immune System Diseases
Sulfamethoxazole
Acquired Immunodeficiency Syndrome
Anti-Infective Agents, Urinary
Enzyme Inhibitors
Folic Acid Antagonists
Pharmacologic Actions
Immunologic Deficiency Syndromes

ClinicalTrials.gov processed this record on November 05, 2009